Foghorn Therapeutics Inc (FHTX)

Jun 13, 2025

Soft Tissue Sarcoma Pipeline 2025: MOA, ROA, FDA-Approved Drugs, And Clinical Trial Progress Assessment By Delveinsight Oncotherapy Science, Foghorn Therapeutics, C4 Therapeutics, Lyvgen Biopharma - MENAFN.com

Jun 13, 2025

Jun 11, 2025

Soft Tissue Sarcoma Pipeline 2025: MOA, ROA, FDA-Approved Drugs, and Clinical Trial Progress Assessment by DelveInsight | OncoTherapy Science, Foghorn Therapeutics, C4 Therapeutics, Lyvgen Biopharma - Barchart.com

Jun 11, 2025

Jun 11, 2025

Trend Tracker for (FHTX) - news.stocktradersdaily.com

Jun 11, 2025

Jun 10, 2025

Millennium Management LLC Raises Stock Position in Foghorn Therapeutics Inc. (NASDAQ:FHTX) - Defense World

Jun 10, 2025

Jun 08, 2025

Foghorn Therapeutics Inc. (NASDAQ:FHTX) Shares Acquired by Wellington Management Group LLP - Defense World

Jun 08, 2025

Jun 07, 2025

Foghorn Therapeutics Inc. (NASDAQ:FHTX) Receives $12.13 Consensus Target Price from Analysts - Defense World

Jun 07, 2025

Jun 03, 2025

BNP Paribas Financial Markets Makes New $61,000 Investment in Foghorn Therapeutics Inc. (NASDAQ:FHTX) - Defense World

Jun 03, 2025

May 29, 2025

Trading (FHTX) With Integrated Risk Controls - news.stocktradersdaily.com

May 29, 2025

May 29, 2025

Northern Trust Corp Purchases 2,873 Shares of Foghorn Therapeutics Inc. (NASDAQ:FHTX) - Defense World

May 29, 2025

May 26, 2025

Foghorn Therapeutics Inc. (NASDAQ:FHTX) Position Increased by D. E. Shaw & Co. Inc. - Defense World

May 26, 2025

May 26, 2025

Lazard Asset Management LLC Acquires New Shares in Foghorn Therapeutics Inc. (NASDAQ:FHTX) - Defense World

May 26, 2025

May 22, 2025

Foghorn Therapeutics Inc. to Participate in Major Upcoming Healthcare Conferences in 2025 - Nasdaq

May 22, 2025

May 22, 2025

Foghorn Therapeutics to Participate in Four Upcoming Investor Conferences - GlobeNewswire

May 22, 2025

May 20, 2025

10,895 Shares in Foghorn Therapeutics Inc. (NASDAQ:FHTX) Acquired by Cubist Systematic Strategies LLC - Defense World

May 20, 2025

May 19, 2025

(FHTX) Trading Report - news.stocktradersdaily.com

May 19, 2025

May 19, 2025

Q2 EPS Estimate for Foghorn Therapeutics Cut by Analyst - Defense World

May 19, 2025

May 19, 2025

Wedbush Expects Weaker Earnings for Foghorn Therapeutics - Defense World

May 19, 2025

May 17, 2025

JMP Securities Reiterates Market Outperform Rating for Foghorn Therapeutics (NASDAQ:FHTX) - Defense World

May 17, 2025

May 15, 2025

Foghorn Therapeutics Inc. (FHTX) Reports Q1 Loss, Misses Revenue Estimates - MSN

May 15, 2025

May 15, 2025

FHTX: JMP Securities Reiterates Market Outperform Rating for Fog - GuruFocus

May 15, 2025

May 15, 2025

FHTX: JMP Securities Reiterates Market Outperform Rating for Foghorn Therapeutics | FHTX Stock News - GuruFocus

May 15, 2025

May 15, 2025

Foghorn Therapeutics Reports Q1 2025 Financial Results - TipRanks

May 15, 2025

May 14, 2025

Foghorn Therapeutics Provides First Quarter 2025 Financial and Corporate Update - GlobeNewswire

May 14, 2025

May 14, 2025

Foghorn Therapeutics: Pioneering Precision Medicine with Innovative Pharmacology and AI Integration - TipRanks

May 14, 2025

May 14, 2025

Foghorn Therapeutics Inc. reports results for the quarter ended March 31Earnings Summary - TradingView

May 14, 2025

May 14, 2025

FHTX Exceeds Revenue Expectations and Advances Pipeline Programs | FHTX Stock News - GuruFocus

May 14, 2025

May 14, 2025

Foghorn Therapeutics Advances FHD-909 Phase 1 Trial - TipRanks

May 14, 2025

May 14, 2025

Foghorn Therapeutics Inc. SEC 10-Q Report - TradingView

May 14, 2025

May 14, 2025

Foghorn Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com

May 14, 2025

May 14, 2025

Foghorn Therapeutics Advances Cancer Drug Pipeline with Strong Financial Results: Phase 1 Trial Shows Promise - Stock Titan

May 14, 2025

May 13, 2025

Foghorn Therapeutics Inc. (NASDAQ:FHTX) Holdings Boosted by Wells Fargo & Company MN - Defense World

May 13, 2025

May 13, 2025

Analysts Set Foghorn Therapeutics Inc. (NASDAQ:FHTX) PT at $12.13 - Defense World

May 13, 2025

May 12, 2025

Ted Myles Joins Cellarity as Chief Executive Officer - Stock Titan

May 12, 2025

May 12, 2025

Barclays PLC Increases Stock Position in Foghorn Therapeutics Inc. (NASDAQ:FHTX) - Defense World

May 12, 2025

May 08, 2025

(FHTX) Trading Advice - news.stocktradersdaily.com

May 08, 2025

May 07, 2025

Renaissance Technologies LLC Acquires 22,500 Shares of Foghorn Therapeutics Inc. (NASDAQ:FHTX) - Defense World

May 07, 2025

May 06, 2025

Foghorn Therapeutics’ SWOT analysis: chromatin pioneer’s stock faces clinical hurdles - Investing.com Nigeria

May 06, 2025

May 05, 2025

Foghorn Therapeutics to Participate in the Citizens Life Sciences Conference - GlobeNewswire

May 05, 2025

May 03, 2025

Foghorn Therapeutics (FHTX) Expected to Announce Quarterly Earnings on Monday - Defense World

May 03, 2025

May 03, 2025

JPMorgan Chase & Co. Purchases 45,565 Shares of Foghorn Therapeutics Inc. (NASDAQ:FHTX) - Defense World

May 03, 2025

May 01, 2025

Foghorn Therapeutics expands board with biotech veterans By Investing.com - Investing.com India

May 01, 2025

May 01, 2025

Foghorn Therapeutics expands board with biotech veterans - Investing.com

May 01, 2025

May 01, 2025

Foghorn Therapeutics Elects Neil Gallagher, M.D., Ph.D., and Stuart Duty to Board of Directors - Nasdaq

May 01, 2025

May 01, 2025

Foghorn Therapeutics Appoints Neil Gallagher and Stuart Duty to its Board of Directors - GlobeNewswire

May 01, 2025

Apr 29, 2025

Foghorn Therapeutics Presents New Preclinical Data on Selective - GuruFocus

Apr 29, 2025

Apr 29, 2025

Geode Capital Management LLC Boosts Stake in Foghorn Therapeutics Inc. (NASDAQ:FHTX) - Defense World

Apr 29, 2025

Apr 28, 2025

FHTX Unveils Promising Preclinical Data at Cancer Research Confe - GuruFocus

Apr 28, 2025